Neumann, Carola Anke
- Creegh Pharmaceuticals, Inc. (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #29,301
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2006 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$398.7K
Full award amounts, FY2023
Award Records
1
Records listing this PI
Award-Linked Rank
#29,301
By linked amount among FY2023 PIs
Earliest Year Loaded
2006
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Neumann, Carola Anke as a PI. Multi-PI records show the full award amount for context.
- 1R41CA281511-01A1R41Contact PISynergize a novel homologous recombination inhibitor with DNA damagingagents in TNBC$398.7Kaward amount
Award organization
Organizations that administered FY2023 awards listing Neumann, Carola Anke as a PI.
FY2023 award administered by Creegh Pharmaceuticals, Inc. ().
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2006First NIH AwardCreegh Pharmaceuticals, Inc.
- 2010$500K Cumulative Funding
- 2012$1M Cumulative Funding
- 2019$2M Cumulative Funding